Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever
https://www.fool.com/investing/2025/06/26/want-decades-of-passive-income-5-stocks-to-buy-now/?source=iedfolrf0000001
Jun 26, 2025 - Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them.
0
5 Dividend Stocks Poised to Profit From the AI Efficiency Boom
https://www.fool.com/investing/2025/06/24/5-dividend-stocks-poised-to-profit-from-the-ai-eff/?source=iedfolrf0000001
Jun 24, 2025 -
0
JNJ says new data buoys TAR-200 monotherapy for bladder cancer
https://seekingalpha.com/news/4432827-jnj-says-new-data-buoys-tar-200-monotherapy-bladder-cancer?source=feed_sector_healthcare
Apr 21, 2025 -
0
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
https://seekingalpha.com/article/4775320-johnson-and-johnson-jnj-q1-2025-earnings-call-transcript?source=feed_sector_transcripts
Apr 15, 2025 -
0
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date
https://seekingalpha.com/news/4427799-jnj-forecasts-2025-profit-dilution-from-intra-cellular-deal-sets-closing-date?source=feed_sector_healthcare
Apr 01, 2025 -
0
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
https://www.fool.com/investing/2024/10/19/all-it-takes-is-2500-invested-in-each-of-these-3-h/?source=iedfolrf0000001
Oct 19, 2024 - Investors looking for dividend stocks at reasonable valuations have come to the right place.
0
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
https://www.fool.com/investing/2024/10/19/want-decades-of-passive-income-2-stocks-to-buy-now/?source=iedfolrf0000001
Oct 19, 2024 - These companies' longtime shareholders have generally been rewarded.
0
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/10/15/johnson-johnson-jnj-q3-2024-earnings-call-transcri/?source=iedfolrf0000001
Oct 15, 2024 - JNJ earnings call for the period ending September 30, 2024.
0
JNJ releases positive data on nipocalimab for myasthenia gravis in adolescents
https://seekingalpha.com/news/4161434-jnj-releases-positive-data-nipocalimab-myasthenia-gravis-adolescents?source=feed_sector_healthcare
Oct 15, 2024 - Johnson & Johnson's phase 2/3 trial of nipocalimab for myasthenia gravis in adolescents shows promising results, meeting primary and secondary endpoints. Read more here.
0
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
https://www.fool.com/investing/2024/10/13/buy-dividend-king-stock-generate-passive-income/?source=iedfolrf0000001
Oct 13, 2024 - Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.
0
Page 1>